LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Stevens-Johnson syndrome due to topical imiquimod 5%.

    Tedman, Alexander / Malla, Utsav / Vasanthakumar, Luke / Buzacott, Katie / Banney, Leith

    Australian journal of general practice

    2020  Volume 49, Issue 10, Page(s) 662–664

    MeSH term(s) Administration, Topical ; Aged ; Blister/etiology ; Blister/pathology ; Conjunctivitis/etiology ; Drug-Related Side Effects and Adverse Reactions/etiology ; Female ; Humans ; Imiquimod/adverse effects ; Imiquimod/therapeutic use ; Oral Ulcer/etiology ; Oral Ulcer/pathology ; Stevens-Johnson Syndrome/complications ; Stevens-Johnson Syndrome/etiology ; Stevens-Johnson Syndrome/pathology
    Chemical Substances Imiquimod (P1QW714R7M)
    Language English
    Publishing date 2020-10-01
    Publishing country Australia
    Document type Case Reports ; Journal Article
    ZDB-ID 2924889-9
    ISSN 2208-7958 ; 2208-794X
    ISSN (online) 2208-7958
    ISSN 2208-794X
    DOI 10.31128/AJGP-11-19-5145
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 2235: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Conditional survival in patients with stage IB-IIIA melanoma undergoing sentinel node biopsy in Queensland: A longitudinal study.

    Tedman, Alexander James / Liyanage, Upekha E / Chong, Sharene / Rowe, Casey / von Schuckmann, Lena A / Malt, Maryrose / Green, Adele C / Smithers, B Mark / Khosrotehrani, Kiarash

    The Australasian journal of dermatology

    2023  Volume 64, Issue 1, Page(s) e34–e40

    Abstract: Background: Tumour characteristics such as thickness and ulceration, along with sentinel lymph node (SLN) status, have been essential in predicting survival in patients with locally invasive melanomas at the time of diagnosis. It is unclear if these ... ...

    Abstract Background: Tumour characteristics such as thickness and ulceration, along with sentinel lymph node (SLN) status, have been essential in predicting survival in patients with locally invasive melanomas at the time of diagnosis. It is unclear if these prognostic factors are relevant 1, 2 or 5 years after diagnosis.
    Objectives: The key aim of this project was to analyse conditional survival in a cohort of Queensland patients with stage IB to IIIA melanomas (American Joint Committee on Cancer's staging system, 8th version) and to test the relevance of clinicopathological prognostic factors for melanoma outcome after varying intervals of survival time.
    Methods: Patients with primary invasive cutaneous melanoma who were referred to a tertiary melanoma clinic and underwent SLN biopsy between 1994 and 2011 were ascertained. The effect of patient and tumour characteristics on melanoma survival were calculated using multivariate Cox proportional hazard models at diagnosis and at variable times after diagnosis.
    Results: The final analysis included 651 patients (average age 49 years, 55.5% male) with stage IB to IIIA melanoma. At diagnosis, and after 1 and 2 years survived, SLN positivity, thickness and ulceration were predictive of 10-year survival since diagnosis. However, once patients survived 5 years, only SLN status was predictive. Overall conditional melanoma survival improved with increasing time survived. Five years after diagnosis, 10-year conditional melanoma survival (MSS) was 91% (95% CI 86%-95%) compared with 85% (82%-88%) predicted at diagnosis. The improvement in MSS was observed mainly for Stage II melanoma patients and not for those with a positive SLN biopsy.
    Conclusions: This study confirms the improvement of prognosis according to time survived since diagnosis suggesting that after 5 years survival the classic prognostic indicators may not have the same influence.
    MeSH term(s) Humans ; Male ; Middle Aged ; Female ; Melanoma/pathology ; Skin Neoplasms/pathology ; Longitudinal Studies ; Queensland/epidemiology ; Lymphatic Metastasis ; Sentinel Lymph Node Biopsy ; Prognosis ; Ulcer/pathology ; Neoplasm Staging ; Retrospective Studies ; Melanoma, Cutaneous Malignant
    Language English
    Publishing date 2023-01-18
    Publishing country Australia
    Document type Journal Article
    ZDB-ID 138052-7
    ISSN 1440-0960 ; 0004-8380
    ISSN (online) 1440-0960
    ISSN 0004-8380
    DOI 10.1111/ajd.13974
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 236: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients.

    Allen, Nicholas C / Martin, Andrew J / Snaidr, Victoria A / Eggins, Renee / Chong, Alvin H / Fernandéz-Peñas, Pablo / Gin, Douglas / Sidhu, Shireen / Paddon, Vanessa L / Banney, Leith A / Lim, Adrian / Upjohn, Edward / Schaider, Helmut / Ganhewa, Aparna D / Nguyen, Jennifer / McKenzie, Catriona A / Prakash, Saurabh / McLean, Catriona / Lochhead, Alistair /
    Ibbetson, Jan / Dettrick, Andrew / Landgren, Anthony / Allnutt, Katherine J / Allison, Clare / Davenport, Rachael B / Mumford, Blake P / Wong, Brittany / Stagg, Brendan / Tedman, Alexander / Gribbin, Hannah / Edwards, Harrison A / De Rosa, Nicholas / Stewart, Thomas / Doolan, Brent J / Kok, Yonatan / Simpson, Kate / Low, Zhi M / Kovitwanichkanont, Tom / Scolyer, Richard A / Dhillon, Haryana M / Vardy, Janette L / Chadban, Steven J / Bowen, David G / Chen, Andrew C / Damian, Diona L

    The New England journal of medicine

    2023  Volume 388, Issue 9, Page(s) 804–812

    Abstract: Background: Immunosuppressed organ-transplant recipients have an increased incidence of, and mortality from, skin cancer. Nicotinamide (vitamin B: Methods: In this phase 3 trial, we randomly assigned, in a 1:1 ratio, organ-transplant recipients who ... ...

    Abstract Background: Immunosuppressed organ-transplant recipients have an increased incidence of, and mortality from, skin cancer. Nicotinamide (vitamin B
    Methods: In this phase 3 trial, we randomly assigned, in a 1:1 ratio, organ-transplant recipients who had had at least two keratinocyte cancers in the past 5 years to receive 500 mg of nicotinamide or placebo twice daily for 12 months. Participants were examined for skin lesions by dermatologists at 3-month intervals for 12 months. The primary end point was the number of new keratinocyte cancers during the 12-month intervention period. Secondary end points included the numbers of squamous-cell and basal-cell carcinomas during the 12-month intervention period, the number of actinic keratoses until 6 months after randomization, safety, and quality of life.
    Results: A total of 158 participants were enrolled, with 79 assigned to the nicotinamide group and 79 to the placebo group. The trial was stopped early owing to poor recruitment. At 12 months, there were 207 new keratinocyte cancers in the nicotinamide group and 210 in the placebo group (rate ratio, 1.0; 95% confidence interval, 0.8 to 1.3; P = 0.96). No significant between-group differences in squamous-cell and basal-cell carcinoma counts, actinic keratosis counts, or quality-of-life scores were observed. Adverse events and changes in blood or urine laboratory variables were similar in the two groups.
    Conclusions: In this 12-month, placebo-controlled trial, oral nicotinamide therapy did not lead to lower numbers of keratinocyte cancers or actinic keratoses in immunosuppressed solid-organ transplant recipients. (Funded by the National Health and Medical Research Council; ONTRANS Australian New Zealand Clinical Trials Registry number, ACTRN12617000599370.).
    MeSH term(s) Humans ; Australia ; Carcinoma, Basal Cell/etiology ; Carcinoma, Basal Cell/prevention & control ; Carcinoma, Squamous Cell/etiology ; Carcinoma, Squamous Cell/prevention & control ; Chemoprevention ; Keratosis, Actinic/etiology ; Keratosis, Actinic/prevention & control ; Niacinamide/administration & dosage ; Niacinamide/therapeutic use ; Quality of Life ; Skin Neoplasms/etiology ; Skin Neoplasms/prevention & control ; Transplant Recipients ; Immunocompromised Host ; Organ Transplantation/adverse effects ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/therapeutic use ; Ultraviolet Rays/adverse effects
    Chemical Substances Niacinamide (25X51I8RD4) ; Antineoplastic Agents
    Language English
    Publishing date 2023-03-01
    Publishing country United States
    Document type Clinical Trial, Phase III ; Journal Article ; Randomized Controlled Trial
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMoa2203086
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.34: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top